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Spontaneous pathologic arterial calcifications in childhood can occur in generalized arterial calcification of infancy (GACI) or in pseu-
doxanthoma elasticum (PXE). GACI is associated with biallelic mutations in ENPP1 in the majority of cases, whereas mutations in
ABCC6 are known to cause PXE. However, the genetic basis in subsets of both disease phenotypes remains elusive. We hypothesized
that GACI and PXE are in a closely related spectrum of disease. We used a standardized questionnaire to retrospectively evaluate the
phenotype of 92 probands with a clinical history of GACI. We obtained the ENPP1 genotype by conventional sequencing. In those
patients with less than two disease-causing ENPP1mutations, we sequenced ABCC6. We observed that three GACI patients who carried
biallelic ENPP1 mutations developed typical signs of PXE between 5 and 8 years of age; these signs included angioid streaks and pseu-
doxanthomatous skin lesions. In 28 patients, no disease-causing ENPP1mutation was found. In 14 of these patients, we detected path-
ogenic ABCC6mutations (biallelic mutations in eight patients, monoallelic mutations in six patients). Thus, ABCC6mutations account
for a significant subset of GACI patients, and ENPP1mutations can also be associated with PXE lesions in school-aged children. Based on
the considerable overlap of genotype and phenotype of GACI and PXE, both entities appear to reflect two ends of a clinical spectrum of
ectopic calcification and other organ pathologies, rather than two distinct disorders. ABCC6 and ENPP1 mutations might lead to alter-
ations of the same physiological pathways in tissues beyond the artery.Introduction
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periarticular soft-tissue calcifications. Some patients may
also develop hypophosphatemic rickets, a presentation
associated with amilder phenotype.6–10 Inactivatingmuta-
tions in ENPP1 (MIM 173335), encoding ecto-nucleotide
pyrophosphatase/phosphodiesterase 1 (NPP1), have been
identified as the underlying defect in about 75% of the
cases of GACI.6,11 NPP1 generates PPi, a major physiologic
inhibitor of calcification that exerts its effects by, among
other things, inhibiting hydroxyapatite crystal growth.12
Moreover, effects of NPP1 on adenosine metabolism also
could modulate arterial calcification.13
Pseudoxanthomaelasticum(PXE [MIM264800])wasfirst
described in 1881,14 and its prevalence is estimated to be 1
in 25,000.15 It is known as an autosomal-recessive disorder,
but autosomal-dominant inheritance has been proposed in
rare PXE cases.16,17 PXE is characterized by ectopicmineral-
ization and fragmentation of elastic fibers of connective
tissues, including skin, vascular walls, and the eyes.18 The
main dermatological features are yellowish papules or pla-
ques of coalesced papules on the neck and in flexural areas
that have typical histological abnormalities. The presence
of fragmented basophilic elastic fibers in the upper and
middle reticular dermis and calcifications of elastic fibers
are characteristic histologic findings of this disorder.
Cardiovascular involvement includes decreased peripheral
pulses, vascular calcifications, and endocardial thick-
ening.19–21 Angioid streaks seen in fundoscopy reflect
disruption of the so-called Bruch’s membrane, which
consists of elastic fibers between the pigmented retinal
epithelium and the choroidea.22 Additionally, PXE can
manifest with gastrointestinal haemorrhage and abnormal
tissue mineralization in different organs, including the
liver, kidneys, spleen, breast, and testes.23,24
Classic PXE results from mutations in the ABCC6
(ATP-binding cassette subfamily C number 6) gene (MIM
603234).25 The ABCC6-transported substrate or substrates,
whichmodulate arterial calcification and other phenotypic
changes of PXE, are not known, and hepatic abnormalities
that have effects on calcification-regulating plasma
proteins such as fetuin have been suggested to at least
partially mediate pathogenesis of PXE.26 In this context,
PXE-like findings have also been found in patients with
b-thalassemia (MIM 613985)27 and have been found to
accompanydeficiency of the vitamin-K-dependent clotting
factors.28 In 2007, mutations in GGCX (MIM 137167) were
reported in several cases with PXE-like cutaneous lesions
and deficiency of vitamin-K-dependent clotting factors.29
GGCX encodes a gamma-glutamyl carboxylase essential
for activation of hepatic coagulation factors and of the
ectopic calcification inhibitor matrix gla protein (MGP).29
Most recently, our group reported on a family with two
sons; the older son presented with PXE and mutations in
ABCC6, and the younger one died of GACI at the age of
15 months.30 Mutation analysis was not performed in
the younger brother. However, retrospective analysis of
the living family members was negative for mutations in
ENPP1. On the basis of these observations, we hypothe-26 The American Journal of Human Genetics 90, 25–39, January 13, 2sized that GACI and PXE might be more closely related
than previously thought. Here we report on three patients
with GACI caused by biallelic mutations in ENPP1. These
patients developed typical signs of PXE in childhood. We
also present the results of the clinical and mutational
analysis of 14 patients who have GACI but do not have
disease-causing mutations in ENPP1 and in whom
ABCC6 mutations were identified.Patients and Methods
Patients
For this study, we used clinical data and DNA material from our
international GACI registry.6 This registry is an ongoing system-
atic collection of phenotypic and genotypic data from patients
with the clinical diagnosis of GACI and currently contains data
from 92 GACI patients of 85 unrelated families (Figure S1, avail-
able online). Diagnosis of GACI was based on the presence of
cardiovascular symptoms associatedwith evidence of arterial calci-
fications with or without stenoses as seen on X-ray or ultrasound
in infancy, periarticular calcifications detected on radiological
studies, or typical histological findings. Patient history and clinical
data were gathered through a standardized questionnaire, which
was sent to the referring physician or geneticist. All patients in
the registry were screened for mutations in ENPP1 as part of the
routine diagnostic analysis.
Clinical and mutational data on a subset of 55 of these patients
have been published before.6 The clinical course of GACI is exem-
plified by a case report on patients 1, 2, and 8 (Supplemental Data).
When available, clinical data on signs of PXEwere evaluated (for
detailed case reports, see Supplemental Data). PXE diagnostic
criteria included characteristic skin involvement, characteristic
histopathologic features of lesional skin,31 and angioid streaks of
the retina.32
The study protocol was approved by the Mu¨nster University
Hospital Ethical Committee and other participating institutional
peer-review human-subject committees. The parents of all subjects
involved in this study gave informed written consent.Mutation Analysis
Genomic DNA was extracted from whole blood. When blood was
unavailable, patient DNAwas extracted from formalin-fixed tissue
blocks.
DNA from 92 patients of 85 unrelated families with clinically
proven GACI was subjected to mutation analysis of ENPP1. Poly-
merase chain reaction (PCR) with 24 primer pairs was used for
amplification of the 25 exons and the flanking splice sites in
ENPP1 (RefSeq accession number NG_008206.1), as previously
described.7 Primer sequences are available upon request. In those
patients with less than two biallelic coding-region or splice-site
mutations in ENPP1, ABCC6 (RefSeq accession number
NG_007558.2) mutation analysis was performed with previously
described ABCC6-specific primers so that all 31 exons and the
exon/intron boundaries would be amplified.33,34 Previously re-
ported sequences35 were used for synthesis of intron-derived
primers specific for PCR amplification of ABCC6 exons 1–9. We
investigated splice-site mutations and aberrant splicing by
sequencing the ABCC6 cDNA. Primer sequences are available on
request. PCR products were directly sequenced bidirectionally
withan ABI 3730 Genetic Analyzer and a BigDye Terminator012
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The Amv3.1 Cycle Sequencing Kit according to the protocol provided by
the manufacturer (Applied Biosystems, Foster City, California,
USA). Mutations were compared with the dbSNP, HGMD, and
ENSEMBL polymorphism databases. The recurrent large deletion
of exons 23–29 (c.2996_4208del) of ABCC6 was screened by PCR
with a previously described set of nested primers.36 For segregation
analysis, parental DNAwas analyzedwith the aim of excluding the
occurrence of two mutations on the same allele.Multiplex Ligation-Dependent Probe Amplification
The specific synthetic probe set for multiplex ligation-dependent
probe amplification (MLPA) analysis of ABCC6, covering 23 of
the 31 exons, was used (SALSA MLPA kit P092 ABCC6, MRC-
Holland, Amsterdam, The Netherlands). The construction of the
kit precludes the generation of signals from the ABCC6 pseudo-
genes. MLPA reactions were performed with the reagents and
recommendations of the ABCC6 MLPA reagent kit and with
100 ng of genomic DNA. The PCR products were separated by
capillary electrophoresis on an ABI 3730 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). The Peak ScannerTM
Software v1.0 (Applied Biosystems, Foster City, CA, USA) was
used for peak identification and fragment sizing. Data analysis
was carried out according to the manufacturer’s recommenda-
tions. All samples were tested in duplicate.Splice-Site Prediction
For analysis of the splice-site mutation of patient #2, there was no
RNA available. Thus, the software NetGene2 v. 2.4 (Center for Bio-
logical Sequence Analysis, Technical University of Denmark DTU)
was used for in silico prediction of aberrant splicing.Results
Cumulatively, we identified biallelic pathogenic mutations
in ENPP1 in 62 of 92 affected patients (data not shown).
Three of these patients developed typical signs of PXE in
childhood (Table 1). Of the remaining 30 GACI patients,
28 patients showed neither splice-site nor coding-region
mutations in ENPP1, and 14 patients were found to carry
ABCC6 mutations (Figure S1). Two unrelated probands of
our cohort carried only one pathogenic ENPP1 mutation
on one allele. Genomic DNA derived from these probands
was also subjected to ABCC6 mutation analysis. None of
these probands carried a potentially pathogenic mutation
in ABCC6.Clinical Features of GACI Patients Who Have PXE
and Carry Mutations in ENPP1
Of the 92 patients of our study cohort, three unrelated
patients, two boys and one girl (patients 1, 2, and 3) who
had generalized arterial calcification of infancy (Table 1;
for detailed case reports on patients 1 and 2 see Supple-
mental Data) presented with clinical features of PXE
in later childhood. In the first male patient (patient 1),
who was born to consanguineous parents and presented
with extensive calcifications of large and medium-sized
arteries, the diagnosis of GACI was already established
in the neonatal period and led to early bisphosphonateerican Journal of Human Genetics 90, 25–39, January 13, 2012 27
Figure 1. Manifestation of GACI and PXE Associated with ENPP1
Mutations
Patient 1, who suffered from generalized arterial calcification in
infancy. X-ray showing extensive peri-articular calcification of
the right shoulder (A) and abdominal CT scan showing a ring-like
calcification of the abdominal aorta (B, arrow) in the neonatal
period. Yellowish papules, located on the frontal part of the neck
when the patientwas 9 years old,were suggestive of PXE (C),which
was histologically proven by the presence of dermal calcium
deposits associatedwithelasticfibers (D) (VonKossa staining,310).treatment. At the age of 8 yr, this patient developed pseu-
doxanthomatous skin lesions, which were proven histo-
logically to reflect calcifications of elastic fibers in the
dermis, as are typical for PXE (Figure 1). Also, the mother
of this proband showed yellowish papules. The female
patient (patient 2), who presented with painful periarticu-
lar calcifications in infancy, showed angioid retinal streaks
suggestive of PXE at the age of 5 yr. At that time, wide-
spread calcifications of the heart and the proximal great
arteries were noted on computed tomography. She had
not received bisphosphonate therapy. Interestingly, both
patients developed hypophosphatemic rickets as well as
deafness due to stapedo-vestibular ankylosis. Additionally,
both patients showed capillary angiomas on different parts
of the skin (Supplemental Data), which had not been
described previously in patients with GACI or PXE. The
third patient (patient 3) presented with left ventricular
hypertrophy in the neonatal period. At 14 months of age,
arterial hypertension was noted, and angiography revealed
severe arterial stenosis of the celiac artery, the superior
mesenteric artery, renal arteries, and both internal and
external carotid arteries. Mutation analysis of ENPP1 in
this boy was performed when the mother had a second
pregnancy, which resulted in a stillbirth at 31 weeks of
gestation; the fetus showed fetal hydrops and aortic root
calcification, suggestive of GACI. A detailed case report on
the two siblings was recently published.8 Most recently,
starting at the age of 8 yr, the surviving boy developed pseu-
doxanthomatous skin lesions around his umbilicus and on
his neck, and these were histologically proven to be typical
PXE lesions.28 The American Journal of Human Genetics 90, 25–39, January 13, 2Mutations in ENPP1 in Three Patients with GACI
and PXE
The homozygous missense mutation c.1612G>C
(p.Asp538His) was detected in exon 16 of ENPP1 in patient
1. Both parents were shown to be heterozygous carriers of
the mutation. This amino acid change affects a conserved
residue located within the catalytic domain of NPP1 and is
therefore predicted to affect enzyme activity (Table 2 upper
panel, Figure 2). In patient 2, the mutation c.795þ1G>A
was detected on the maternal allele, and c.1756G > A
(p.Gly586Arg) was detected on the paternal allele. The
mutation c.795þ1G>A is located at the exon-intron
boundary of exon 7 and is predicted to affect a splice donor
site (NetGene2 v. 2.4, Center for Biological Sequence Anal-
ysis, Technical University of Denmark DTU) and therefore
to lead to abnormal splicing. The mutation c.1756G>A
(p.Gly586Arg) leads to a change of the conserved polar
amino acid glycine to the polar charged amino acid argi-
nine in the catalytic domain of the NPP1 protein and
thus most likely affects NPP1 enzymatic activity. Patient
3 was compound heterozygous for the two nonsensemuta-
tions c.783C>G (p.Tyr261X) in exon 7 and c.878_879
delAA (p.Lys293fsX4) in exon 8,8 both of which are pre-
dicted to lead to a severely truncated protein. Sequence
analysis of the exons and flanking intronic regions of
ABCC6 in each of the three patients did not show any aber-
ration.
Clinical Features of GACI Patients Carrying ABCC6
Mutations
30 patients with GACI and with less than two coding
regions or splice-site mutations in ENPP1 were screened
for mutations in ABCC6. Mutations in ABCC6 were de-
tected in 14 of these patients (Table 3). Homozygous muta-
tions were found in two patients, compound heterozygous
mutations in six, and in six patients only one mutation
could be identified.37,38
The eight patients carrying biallelic ABCC6 mutations
were of different ethnic backgrounds and presented in
early infancy with widespread calcifications of the aorta
and medium-sized arteries, including coronary arteries
and renal arteries (Table 3). Four of these patients (patients
4, 5, 7, and 11) were severely affected and died of myocar-
dial infarction and cardiac failure within the first three
months of life. Autopsy performed in one patient (patient
4) revealed the typical histological features consisting of
calcification of the internal elastic lamina, myointimal
proliferation in the coronary arteries, and consequent
severe arterial stenosis (Figure 3D). Interestingly, in one
patient, generalized arterial stenoses were demonstrated
without any evidence of arterial calcification (patient #5).
This patient died of myocardial infarction at the age of
8 weeks. Another patient (patient 8) presented with periar-
ticular calcifications of the shoulder joints and the hip
joints (Figures 3A and 3B). This patient also developed
diffuse cerebral white matter disease leading to cystic ence-
phalomalacia, which is quite uncommon in GACI.012
Table 2. Functional Consequences of Mutations in ENPP1 and ABCC6
Exon DNA Change Amino Acid Change Patient Functional Consequences References
ENPP1
7 c.783C>G p.Tyr261* 3 truncated protein 6, 8, 11
IVS7 c.795þ1G>A Loss of splice site 2 predicted loss of donor splice site, aberrant
splicing
new
8 c.878_879delAA p.Lys293fs*4 3 truncated protein 6, 8, 11
16 c.1612G>C p.Asp538His 1 affects conserved aa in catalytic domain,
negatively charged aa changed
to neutral/positively charged aa
new
18 c.1756G>A p.Gly586Arg 2 affects conserved aa in catalytic domain,
polar aa changed to polar, positively
charged aa
new
ABCC6
4 c.450_451insC p.Ala151Argfs*45 5 truncated protein new
9 c.1064T>G p.Leu355Arg 14 affects conserved aa in transmembrane
domain, non-polar aa changed into polar,
positively charged aa
25, 42
9 c.1171A>G p.Arg391Gly 9, 15, 16 affects conserved aa in intracellular
domain, polar, posively charged
aa changed into polar aa
25, 42, 43
12 c.1552C>T p.Arg518* 6, 10 truncated protein 25, 42
13 c.1769C>T p.Ser590Phe 12 affects aa in transmembrane domain,
conserved in bovine, chicken and fungus
new
IVS21 c.2787þ1G>T p.Arg929fs*1 4 truncated protein 25, 42
23 c.3105_3107delCTTa p.Phe1036del 6 loss of one conserved aa in intracellular
domain
25 (c.3106delTTT
p.Phe1036del)
24 c.3340C>T p.Arg1114Cys 13 affects conserved aa in intracellular
domain, polar charged aa changed
into non-polar aa, possible formation
of incorrect disulfide bonds
25, 42, 44
24 c.3421C>T p.Arg1141* 11 truncated protein 25, 33, 34, 47
26 c.3662G>A p.Arg1221His 7 affects conserved aa in intracellular domain 42, 45
IVS26 c.3736-1G>A p.Ala1246fs*26 4 truncated protein 25, 42, 47
28 c.3940C>T p.Arg1314Trp 5, 8, 17 affects conserved aa in ATP-binding domain 25, 34, 42, 46
23-29 c.2996_4208del p.Ile1000Trpfs*60 9 truncated protein 36
a The mutation p.Phe1036del is already known,25 although the known DNA change is c.3106_3108 delTTT. The DNA change c.3105_3107delCTT leading
to the same amino acid change, p.Phe1036del, is not described in the literature.In six additional patients we were able to detect only
one potentially pathogenic mutation in ABCC6. One of
these patients was the recipient twin of a twin-to-twin
transfusion syndrome. He died of myocardial ischemia
at the age of 5 months, whereas the donor twin
survived.6,7,39,40 The other patients had a more favorable
clinical course; for example, one female proband who pre-
sented with GACI41 developed epilepsy at the age of 20 yr
and was 31 yr old at the time of this study (Table 3, patient
14). Information on dermal elastorrhexis or retinal
changes on this patient was not available.
Mutations in ABCC6 in Patients with GACI
Thirteen different mutations in ABCC6 were identified in
patients withGACI. These included sixmissensemutationsThe Am(c.1064T>G [p.Leu355Arg], c.1171A>G [p.Arg391Gly],
c.1769C>T [p.Ser590Phe], c.3340C>T [p.Arg1114His],
c.3662G>A[p.Arg1221His, andc.3940C>T [p.Arg1314Trp]),
two nonsense mutations (c.1552C>T [p.Arg518*],
c.3421C>T [p.Arg1141*]), one small deletion (c.3105_3107
delCTT [p.Phe1036del]), one small insertion leading to
a frameshift (c.450_451insC [p.Ala151Argfs*45), two
splice-site mutations (c.2787þ1G>T [p.Arg929fs*1],
c.3736-1G>A [p.Ala1246fs*26]), and one large deletion
(c.2996_4208del [p.Ile1000Trpfs*60]). Of these, 11 muta-
tions have been previously described as disease-causing
in patients with PXE (p.Leu355Arg,25,42 p.Arg391
Gly,25,42,43 p.Arg1114His,25,42,44 p.Arg1221His,42,45 p.Arg
1314Trp,25,34,42,46 p.Arg518*,25,42 p.Arg1141*,25,33,34,47
p.Phe1036del,25 p.Arg929fs*1,25,42 p.Ala1246fs*26,25,42,47erican Journal of Human Genetics 90, 25–39, January 13, 2012 29
NH2
COOH
Transmembrane
domain
Somatomedin-B-like
domains
Phosphodiesterase-like
catalytic domain
Nuclease-like
domain
IVS 7+1G>A 
Asp538His
Gly586Arg
77
97
104
189
191
591
654
925
Tyr261*
Lys293fs*4
Figure 2. Schematic Representation of Human NPP1 Shows
Mutations Identified in GACI Patients with PXE Features in the
Current Study
Amino acid positions in functional domains according to
spP22413 (SwissProt) ¼ Q5T9R6 (UniProtKB/TREMBL) for human
NPP1.and p.Ile1000Trpfs*6036). Only four mutations, namely
p.Arg391Gly, p.Arg518*, p.Arg1141*, and p.Arg1314Trp,
were found in more than one patient; all other mutations
occurred only once.
All mutations that led to amino acid exchanges involved
amino acids located within cytosolic or transmembrane
domains of ABCC6, reflecting the potential importance of
these regions in terms of protein function. Localization of
mutations in the ABCC6 protein is visualized in Figure 4.
The missense mutations p.Leu355Arg, p.Arg391Gly,
p.Ser590Phe, p.Arg1114His, and p.Arg1221His are pre-
dicted to result in alterations of the ABCC6 conformation.
Some of these alterations might affect the function more
than others, and the effect might be particularly strong at
conserved positions. For the second ATP-binding domain,
where the mutation p.Arg1314Trp of the current study is
located, it is known that mutations are able to completely
abolish the transport activity of the ABCC6 protein.48 The
missense mutations cause amino acid substitutions that
lead to the introduction of a residue with different phys-
ical-chemical properties (Table 2, lower panel).
Multiple sequence alignment of ABCC6 across species
showed changes in highly conserved amino acids, except30 The American Journal of Human Genetics 90, 25–39, January 13, 2for the mutation p.Ser590Phe, which is conserved in
bovines, chicks, and fungus (Figure 5). The nonsense
mutations (p.Arg518* and p.Arg1141*), the frameshift
mutation (p.Ala151Argfs*45), and the large deletion of
exons 23–29 (p.Ile1000Trpfs*60) are predicted to result in
the production of a truncated protein. These polypeptides
are devoid at least of an intact second ATP-binding domain
and are therefore predicted to be nonfunctional.
It should be noted that the mutation p.Phe1036del
has been described before in PXE patients as being
caused by the DNA change c.3106_3108 delTTT.25 The
patient presented here, however, carried the mutation
c.3105_3107delCTT, which led to the same in-frame dele-
tion of phenylalanine at position 1036.
The splice-site mutations c.2787þ1G>T and c.3736-
1G>A have been predicted to alter splicing.34,47 To deter-
mine the effect of these two mutations on the protein, we
sequenced cDNA from our patients. Both splice-site muta-
tions lead to a new splice site and aberrant splicing (Supple-
mental Data). This causes a frameshift and results in an
abnormal and truncated protein.
Two disease-associated ABCC6 mutations are presented
here. The DNA change c.1769C>T (p.Ser590Phe) was
found in a heterozygous state in a patient with only
one mutation. It is located in the transmembrane
domain of the protein. The DNA change c.450_451insC
(p.Ala151Argfs*45) was also found in a heterozygous
state in one patient. This small insertion leads to a frame-
shift and to generation of an abnormal and truncated
protein. These two mutations were not present on 200
alleles from 100 individuals from corresponding ethnic
backgrounds and could therefore be excluded as
polymorphisms. Type and severity of the ABCC6 muta-
tions identified in our cohort of GACI patients did not
differ from those previously found to be associated
with PXE.Discussion
PXE andGACIhave been considered to be twodistinct enti-
ties in the past and have been primarily linked to ABCC6
and ENPP1, respectively. In the current study, we showed
that biallelic mutations in ABCC6 account for a substantial
number of typical GACI cases, which involve typical
diseasemanifestations such as widespread arterial calcifica-
tions, arterial stenosis, peri-articular calcifications, and,
occasionally, hypophosphatemic rickets (patient 12). Addi-
tionally, in six patients with clinical GACI, we detected
mono-allelicABCC6mutations. These patients, froma clin-
ical point of view, do not significantly differ from the
patients carrying biallelic ABCC6 mutations. Although
MLPA failed to detect large deletions on the other allele in
these patients, it is possible that the ABCC6 mutation on
the allele in trans in these patients was missed by our
exon-based sequencing approach, e.g.,mutations in regula-
tory untranslated regions of ABCC6 could be present,012
which might influence transcription or translation. In this
respect, the absence ofmutations in either ENPP1 orABCC6
in some of the patients might have been due to a failure to
detect them with our approach.
Plomp et al. investigated the possibility of autosomal-
dominant inheritance of PXE,16 and the authors came to
the conclusion that part of the phenotype in affected
family members of individuals with PXE might be due to
expression in heterozygous carriers and that autosomal-
dominant inheritance is extremely rare. In this respect, it
is still a matter of debate whether loss-of-function muta-
tions on one allele are sufficient to cause a cardiovascular
complication of the disease.17 Digenic inheritance was
alternatively suggested by Li et al., who detected the pres-
ence of heterozygous mutations in both ABCC6 andGGCX
in affected individuals with PXE.49 However, a mutation in
ENPP1 in trans was ruled out in six patients of our study,
whereas a copy-number variation in ENPP1 or the presence
of a larger deletion was not. Mutation analysis of GGCX
was beyond the scope of our study and was therefore not
performed in our cohort.
With the exception of ABCC6mutations c.450_451insC
(p.Ala151Argfs*45) and c.1769C>T (p.Ser590Phe),
reported here for the first time, all of the ABCC6
mutations detected in our study cohort have already
been described previously in typical PXE patients, who pre-
sented a much milder phenotype than our GACI
patients.25,34,36,42–47 In our study, of a population clearly
selected for severe arterial calcification, we discovered
that ABCC6 mutations can be associated with a much
more severe phenotype, including death in infancy from
myocardial infarction, than was previously known. Inter-
estingly, the ABCC6 mutation p.Arg1141*, which was
present on one allele in our cohort’s patient 10, who pre-
sented with widespread arterial calcifications and arterial
hypertension at the age of 3 yr, is present in 0.8% of certain
populations and was reported to predispose individuals to
premature coronary artery disease when it was present on
one allele.50 However, most recently, four large replication
studies failed to ascertain this association.51
We conclude that the phenotypic spectrum of disease
associated with ABCC6 mutations is much broader than
was previously assumed. In fact, we now show that the
infantile phenotype of patients carrying ABCC6mutations
can be indistinguishable from the phenotype associated
with ENPP1 mutations (Figure 6). Notably, this includes
the presence of hypophosphatemic rickets, as evident in
our cohort’s patient 12, who carried the mutation
p.Ser590Phe on one allele in ABCC6. Importantly, hypo-
phosphatemic rickets has been found to be associated
with mutations in ENPP1.9,10
The fact that the same ABCC6 mutations can cause the
severe GACI phenotype associated with myocardial infarc-
tion and death in early infancy in one patient and the rela-
tively mild phenotype of PXE in another patient warrants
further explanation. It is likely that mutations in modi-
fying genes may play a role here. It would therefore beThe Amreasonable to screen GACI patients carrying ABCC6 muta-
tions for mutations in genes encoding other inhibitors of
artery calcification.52 Such genes might include MGP
(MIM 154870), TNFRSF11B (MIM 602643), Smad6 (MIM
602931), CA2 (MIM 611492), FBN1 (MIM 134797), KL
(MIM 604824), SPP1 (MIM 166490), TIF1A (MIM
603406) and AHSG (MIM 138680).
Three patients of our study cohort, who presented with
GACI and carried biallelic ENPP1 mutations, developed
clinical signs of PXE, including angioid streaks and histo-
logically proven calcifications of elastic skin fibers.
Though fully penetrant, clinical findings of PXE are rarely
present at birth, and skin findings only rarely become
recognizable before the second or third decade of
life.18,23 Thus, given the poor prognosis of severe GACI,
affected patients might die of the cardiovascular complica-
tions of the disease before they develop typical signs of
PXE, and this might be the reason that no previous case
of GACI has been described in the PXE literature. Accord-
ingly, the number of patients showing PXE lesions would
be low in any GACI cohort with individuals carrying
ENPP1 mutations. Also, more subtle PXE characteristics,
including angioid streaks of the retina and peau d’orange
skin lesions might frequently be overlooked in routine
clinical examinations. As a limitation of the retrospective
scope of our registry, characteristic signs and symptoms
of PXE might have been overlooked in our cohort of
surviving GACI patients. Hence, the true number of
patients carrying ENPP1 mutations and showing PXE
lesions might be higher even in our cohort. On the basis
of our observation of the development of PXE in individ-
uals with GACI, we propose that all patients with GACI
who survive the critical period of infancy6 should carefully
be investigated for typical skin and ophthalmologic PXE
lesions later in life.
The fact that mutations in ENPP1 and ABCC6 manifest
in overlapping clinical phenotypes suggest that the patho-
physiologies of GACI and PXE are intertwined.
NPP1 is a major physiologic generator of extracellular
PPi, a potent inhibitor of hydroxyapatite crystal formation
and growth.12 Extracellular PPi depletion caused by loss-of-
function mutations in ENPP1 is one of the driving forces
leading to arterial and articular cartilage calcification in
GACI and in the respective mouse model, the ttw/ttw
mouse carrying a spontaneous nonsense mutation in
Enpp1.52 NPP1 expression, though relatively restricted,
occurs in the liver, epithelium of the renal proximal
tubule, salivary-gland epithelium, arterial wall,53 chondro-
cytes, osteoblasts, mature plasma cells, and skin fibro-
blasts.7 Decreased local expression of NPP1 at the sites of
the observed ectopic calcifications is probably critical.54
For example, deficiency of NPP1 in choroideal arteries
might lead to the eyemanifestations of PXE in our patients
carrying ENPP1mutations, and NPP1 deficiency in dermal
fibroblasts might lead to skin calcification in affected
patients. Whether deficient NPP1 in the liver modulates
circulating levels of calcification inhibitors beyond PPi toerican Journal of Human Genetics 90, 25–39, January 13, 2012 31
Table 3. Clinical and Mutational Data of Patients Who Have a GACI Phenotype and Carry Mutations in ABCC6
Family Patient Sex
Geo-
graphic
Origin
Consan-
guinity
Affected/
Nonaffected
Siblings
Arterial
Calci-
fications
Periarticular
Calcifications
Cardiovascular
Complications
Additional
Abnormalities
Bisphos-
phonate
Therapy
Age at
Data
Collection
Age at
death Histology
DNA
Change in
ABCC6
Amino Acid
Change in
ABCC6 References
4 4 f Canada no 1/0 a,c,p,r,d no occlusion of
right coronary
artery,
myocardial
infarction,
tubular
calcification
in kidneys
no 6 1/2 weeks autopsy:
calcification
of internal
elastic laminae &
elastic tissue in
vessel wall,
intima
proliferation
c.[2787þ1G>T];
[3736-1G>A]
p.[Arg929fs*1];
[Ala1246fs*26]
6 (patient 50),
11, 37
5 5 m Afro-
Caribia
no 1/0 no no generalized
arterial
stenosis;
myocardial
infarction;
hypertension
no 8 weeks no c.[450_451insC];
[3940C>T]
p.[Ala151Argfs*45];
[Arg1314Trp]
6 6 f Armenia no 1/0 a, c, r, d \ oliguria; edema
of ankles; failure
to thrive
no 2 9/12 years no c.[1552C>T];
[3105_3107delCTT]
p.[Arg518*];
[Phe1036del]
7 7 m Spain no 1/ 1 v,d no cardiac failure;
hypertension
fetal hydrops;
renal failure
no 3 months c.[3662G>A];
[3662G>A]
p.[Arg1221His];
[Arg1221His]
8 8 m USA no 1/1 a, p, c, r, d stippled
calcifications
of proximal
epiphyses
of humeri,
femora,
pelvic cartilage,
larynx and
mandible
cardiac
dysfunction,
hypertension;
respiratory
insufficiency
diffuse white
matter disease
with cystic
encephalomalacia,
hyperbilirubinemia,
anemia and
thrombocytopenia
no 5 years no c.[3940C>T] ;
[3940C>T]
p.[Arg1314Trp];
[Arg1314Trp]
9 9 m USA d no hypoplastic
kidney
short-term
pamidronate
2 months no c.[1171A>G] ;
[c.2996_4208del]
p.[Arg391Gly];
[Ile1000Trpfs*60]
10 10 m Spain no 1/0 splenic
arteries,
pancreas,
nephro-
calcinosis
no severe arterial
hypertension,
cardiomegaly
psychomotor
retardation,
abdominal
distension
no 3 years c.[1552C>T];
[3421C>T]
p.[Arg518X];
[Arg1141*]
3
2
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Table 3. Continued
Family Patient Sex
Geo-
graphic
Origin
Consan-
guinity
Affected/
Nonaffected
Siblings
Arterial
Calci-
fications
Periarticular
Calcifications
Cardiovascular
Complications
Additional
Abnormalities
Bisphos-
phonate
Therapy
Age at
Data
Collection
Age at
death Hist ogy
DNA
Change in
ABCC6
Amino Acid
Change in
ABCC6 References
11 11 f France no 1/2 c,d no severe arterial
hypertension,
cardiac failure
etidronate
up to
30 mg/kg
per day
6 weeks c.[3421C>T];
[3940C>T]
p.[Arg1141*];
[Arg1314Trp]
12 12 m Pakistan yes 2/3 a,p,v hips,
shoulders
hypophos-
phatemic
rickets
no 17 years c.[1769C>T];[?] p.[Ser590Phe] ;[?] 6 (patient 45), 11
13 13 m Latin
America
no 1/2 d multiple sites etidronate 3 3/4 years c.[3340C>T];[?] p.[Arg1114Cys] ;[?] 6 (patient 47)
14 14 f Nether-
lands
no 2/2 a, d mentally
retarded;
developed
epilepsia
at 20 years
no 31 years mus e biopsy:
calci cation &
sten is
of p imyseal
arter les,
dege eration of
elast fibres
in ve sel wall
c.[1064T>G];[?] p.[Leu355Arg] ;[?] 41
15 15 m USA no 2 (twins)/ 0 a,c,p,
cerebral
vessels
no cardiac
ischemia;
respiratory
insufficiency;
hypertension
recipient of
twin-to-twin transfusion
no 5 months c.[1171A>G];[?] p.[Arg391Gly] ;[?] 6 (patient 51),
7, 39, 40
15 16 m USA no 2 (twins)/0 a,p no donor of twin
to twin
transfusion
no 7 years c.[1171A>G];[?] p.[Arg391Gly];[?] 6 (patient 52),
7, 39, 40
16 17 f South
Africa
no 1/0 a, spleen,
pancreas,
nephro-
calcinosis
no failure to
thrive, arterial
hypertension,
cardiac failure
onset of
symptoms
at 2 1/2 years
no 3 years c.[3940C>T];[?] p.[Arg1314Trp] ;[?] 38
Abbreviations are as follows: A, aorta; c, coronary arteries; d, diverse arteries; p, pulmonary artery; and r, renal arteries.
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Figure 3. Manifestation of GACI Associated with ABCC6 Muta-
tions
Patient 8, who presented with cyanosis, respiratory distress, and
truncal edema on the first day of life. (A) X-ray showing stippled
periarticular calcifications of the right shoulder (arrow) and (B)
the pelvic cartilage (left arrow) and the left hip joint (right arrow).
(C) Abdominal ultrasound showing increased echogenicity of the
aortic wall (arrows). (D) A cross-section of a coronary artery from
patient 4, who died of myocardial infarction at the age of 6 weeks,
shows disruption of the calcified internal elastic lamina (arrows)
and massive intima proliferation (HE staining, 32.5). An asterisk
indicates the intraarterial vascular catheter.contribute to widespread dystrophic calcifications in GACI
and PXE remains to be determined. Bisphosphonates,
which have been used as synthetic analogs of PPi to
suppress arterial calcification in GACI patients,6 failed to
protect an individual (patient 1 in our cohort) carryingMembrane
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Figure 4. Schematic Representation of Human ABCC6 Shows Mut
A darkened line indicates an ATP bindingmotif, a circled P indicates a
for patients described in this paper, and a dashed line indicates amult
termination; del, deletion. Transmembrane helix positions are accor
34 The American Journal of Human Genetics 90, 25–39, January 13, 2ENPP1 mutations from developing PXE lesions later in
childhood. However, one may speculate that prolonged bi-
sphosphonate therapy might have been beneficial for this
individual.
ABCC6 encodes MRP6 (ABCC6), a transmembrane
protein primarily expressed in the liver and a member of
the ATP-binding cassette (ABC) transporter family. It has
been proposed that absence of ABCC6 activity, primarily
in the liver, results in the deficiency of circulating factors
and thereby causes deficiency of physiological inhibition
of artery calcification even when calcium and phosphate
homeostasis are normal.42 This hypothesis is supported by
the finding that when muzzle skin from wild-type mice
was grafted onto the back of Abcc6/mice, mineralization
of the vibrissae was observed.55 Furthermore, serum from
PXE patients, when added to tissue-culture medium of
fibroblasts, altered the expression of elastin.56 Also, it was
hypothesized that reduced g-carboxylation of MGP is
amajorpathogenic factor contributing to the increasedarte-
rial mineralization in PXE because reduced g-glutamyl
carboxylation of MGP was demonstrated in the serum, in
the liver, and in various calcified tissues of Abcc6/mice57
as well as in human PXE skin lesions.30,58 It was therefore
postulated that ABCC6 participates in transmembrane
transport and redistribution of vitamin KH2, an obligatory
co-factor of g-glutamyl carboxylase,59,60 especially when
conjugated to glutathione. However, the finding that
supraphysiological doses of vitamin K, an inducer of
g-glutamyl carboxylation of MGP, failed to compensate for
increased tissue mineralization in Abcc6/ mice61,62 did
not substantiate this hypothesis.
Interestingly, mutations in GGCX, encoding g-glu-
tamyl carboxylase, cause a much milder phenotypeCOOH
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ations Identified in GACI Patients in the Current Study
putative phosphoserine, filled-in circles indicate sites of mutations
i-exon deletion. Abbreviations are as follows: fs, frameshift; *, chain
ding to sequence accession number O95255 for human ABCC6.
012
+(Ala151Argfs*45) +(Leu355Arg) +(Arg391Gly) +(Arg518*)
Human       ..--CFVLPATNAAQQASGAGFQ..161   ..PAWKGYLLAVLMFLSACLQTL..365   ..LRSAITGLVYRKVLALSSGSK..401   ..GAFLDRVLGIR-GQELGALRT..527 
Mouse       ..--CCILPGINTVQQASAGNLR..167   ..SAWTGWLLAVLMFAAACLQTL..353   ..LRTAITGLVYRKVLVLSSGSR..399   ..HAFLERLLHIR-GQELSALKT..525 
Bovin       ..LLCALAILRSKIMTALKEDAR..166   ..PEWQGYFYTALLFISACLQTL..379   ..IKTAVIGAVYRKALVITNAAR..415   ..LAFKDKVLAIR-QEELKVLKK..541 
Chick       ..LLCATVIFRSKIMLALNTDTE..166   ..PNWQGYFYTGLLFVCACLQTL..378   ..LKTAIVGVIYRKALVITNSAR..414   ..LAFREKVLEIR-QKELKVLKK..540 
Frog        ..TVCAIIPFRSKVMASARQGQV..165   ..PSWWGFCIAVLMFLTSLVQTL..373   ..LRSAITGIIYRKSLVITNSAK..409   ..PSFAQKVLEIR-NKELNILKK..535 
Fish        ..VVCAVFQFQTLLREALSQG-I..168   ..YAWTGYLYAVLLVLVAFVQSV..395   ..VRTAIMAAVYKKALVVSNDSR..431   ..TSFEAQVQEIR-EKELKVMRK..557 
Roundworm   ..VVCGVPELRYYITGRLYKEYE..168   ..PMWIGVSIALLMFLSSLLQSM..352   ..IRSVLTSAVYTKTLNLSNEAR..388   ..KSMEKMVLEVR-EKEIRVLKK..514 
Mosquito    ..MFFGIIQLRTELQNKELRGDV..161   ..PGWQGVMITFGLFATSLLIAL..362   ..IRTGLISGIYRKALRISSSAK..398   ..KSFQDTILEVR-DKEIGILKK..524 
Fungus      ..TIAYGVKLRSLVSQKAYQDQL..168   ..PVISGVAIALAMFLVSVTQTI..361   ..VKSALTAMIYTKSLRLSSEGR..397   ..TAFMNKLSHIRNDLELNTLRK..524 
Slime mould ..---------------------..21    ..SILKGILLCCLLCLCVLGQSI..169   ..VRGALAAKIFEKTLKLSNASR..205   ..NFFINKIDGQR-KQELKNIFL..332 
                                                 *      :       ::          ::  : . :: * * ::. .:                :   :   *   *:
+(Ser590Phe)                   +(Arg929fsX1)                  +(Ile1000Trpfs*60)             +(Phe1036del)
Human       ..AQAFLPFSIHSLVQARVSFDR..600   ..PAGKDSIQYGRVKATVHLAYL..941   ..IFGLLGCLQAIGLFASMAAVL..1010  ..WDVVRSPISFFERTPIGHLLN..1046
Mouse       ..AQAFLPFSVHCIVQARVSFDR..598   ..TAEEDSVRYGRVKITIYLSYL..936   ..VFGLLGCLQAIGLFASMAAVF..1025  ..WDVARSPIGFFERTPVGNLLN..1041
Bovin       ..PLNILPMVISSIVQASVSLKR..615   ..LVEADKAQTGQVKLSVYWDYM..968   ..VYGALGISQGITVFGYSMAVS..1037  ..HNVLRSPISFFERTPSGNLVN..1073
Chick       ..PLNILPMVISSIVEASVSLKR..612   ..LTEADTAKTGRVKATVYWEYM..963   ..VYGALGISQGIAVFGYSMAVS..1032  ..HNVLRSPMSFFERTPSGNLVS..1068
Frog        ..PLNMLPQVISNLAQASVSIKR..606   ..LYQTETTETGRVKMTVFWQYM..969   ..VYAALGILQGLLVMTSSFSLA..1038  ..DNKMHTPQSFYDTTPIGRIIN..1074
Fish        ..PLAMLPQLISIMVQTSVSKKR..627   ..LIEKEMMETGRVKFSVYLQYL..991   ..VFGALGLAQGFLVFFGTILLA..1064  ..TNILKVPMMFFDTTPSGRIVN..1100
Roundworm   ..PLAVFAMVFSQAVQCSASNTR..585   ..LIEKEAVETGKVKFEVYMSYF..966   ..IYAVLGMGQATSVCAASIIMA..1040  ..ENIMRSPMAFFDVTPLGRILN..1076
Mosquito    ..PLGWLPMMVTFAMQAWVSVKR..593   ..LIEKEESATGAVTLAVYLKYT..938   ..VYGALGGIQSIALFISSVALG..1007  ..ESSMKMPMSFFDTTPLGRIIN..1043
Fungus      ..PLSILPMVITSIIEASVAVRR..597   ..KQTQETSQQGKVKWSVYGEYA..965   ..IYLAWGLGSSILVILQNLILW..1033  ..FSIFRSPMSFFETTPSGRILN..1070
Slime mould ..PLIRLPYDIFKAIGLIPSVKR..404   ..LLVKEDKNEGEVEFNVYKKYF..770   ..-YYLLIFGTFVVILMIRILLL..836   ..KSVTYASCRFFDTNPSGRILN..873
              .   :.  .        :  *              :    * *   :.  *            :          :      :            .    .  *:: .* *.::.
           +(Arg1114Cys)                  +(Arg1141*)                    +(Arg1221His) +(Ala1246fs*26)
Human       ..LYVVSSCQLRRLESASYSSVC..1124  ..FQGSTVVRAFRTQAPFVAQNN..1151  ..QVTQTLQWVVRNWTDLENSIVSVERMQDYAWTPKE-----------APWRLP..1251
Mouse       ..LYVATSCQLRRLESARYSSVC..1119  ..FQGSLVVRAFRAQASFTAQHD..1146  ..QVTQTLQWVVRSWTDLENSMVAVERVQDYARIPKE-----------APWRLP..1246
Bovin       ..FYVASSRQLKRLESVSRSPVY..1151  ..LLGVSVIRAFEEQERFIRQSD..1178  ..QVTTYLNWLVRMSSEMETNIVAVERLKEYSETEKE-----------APWQIQ..1278
Chick       ..FYVATSRQLKRLESVSRSPVY..1146  ..LLGVSVIRAFEEQKRFIKQND..1173  ..QITAYLNWLVRMTSDLETNIVAVERVKEYAEMEKE-----------AEWSIE..1273
Frog        ..FYVATSRQLKRLESVSRSPIY..1152  ..ITGASIIRAYGRQNSFIVLSD..1179  ..QVTMSLNWMVRMTSDLETNIVAVERVKEYAENETE-----------APWHIE..1279
Fish        ..FYVATSRQLRRLDSVSRSPIY..1178  ..VSGLSVIRAYGHQDRFLKHNE..1205  ..NVTQTLNWLVRMTSELETNIVAVERVREYAEIQNE-----------APW-VT..1304
Roundworm   ..FYVSTSRQLKRLESASRSPIY..1148  ..ISGQSTIRAYNEQMRFTRESE..1148  ..NITQTLNWAVRMTSELETNIVAVERINEYTITPTE-----------DVWQKG..1248
Mosquito    ..VYIATSRQLKRLESVTRSPIY..1121  ..IQGASSIRAYGVVDKFIRESQ..1175  ..QISATLSFMVRMTAEVETNIVAVERLEEYTVLPRE-----------GNNS-Q..1276
Fungus      ..YYLRTSRELKRLDSVTRSPIY..1148  ..LGGISTIRGYRQENRFALENE..1175  ..QITQSLNWIVRQTVEVETNIVSVERVLEYANLPSE-----------APDVIF..1278
Slime mould ..LYRPSARELNRWESITVSPIF..951   ..YNGLLTIRTYKQESRFIKEMF..978   ..SLNGYLSWGIRRIVDLEVKMNSFQRIQSYIEIPKEGNKLVSTNSNEVDNHTI..1087
               *  :: :*.* :*   *.:             *   :* :     *               .:.  *.: :*   ::* .: :.:*: .*     *
                             +(Arg1314Trp) 
Human       ..GRTGAGKSSLASGLLRLQEAAEGGIW..1324 
Mouse       ..GRTGAGKSSLAWGLLRLQEAAEGNIW..1319 
Bovine      ..GRTGAGKSSLTLGLFRIKESAEGEII..1351 
Chicken     ..GRTGAGKSSLTLGLFRINEAAEGEII..1346 
Frog        ..GRTGAGKSSMTLCLFRILEPAEGIVK..1352 
Fish        ..GRTGAGKSSLTNCLFRIVEAADGRIL..1377 
Roundworm   ..GRTGAGKSSLTLALFRIIEADGGCIE..1348 
Mosquito    ..GRTGAGKSSLTLGLFRIVEAAGGQIV..1319 
Fungus      ..GRTGAGKSSLTLALFRIIEAAGGSIS..1351 
Slime mould ..GRTGAGKTTIASSLFRMVECSKGLIL..1160 
*******::::  *:*: *   * :
Figure 5. Multiple Alignment around the Mutation Sites of ABCC6 Sequences from Different Organisms
Human, Homo sapiens (O95255); mouse, Mus musculus (Q9R1S7); bovine, Bos taurus (Q8HXQ5); chick, Gallus gallus (Q5F364); frog,
Western claw frog, Xenopus tropicalis (A9JRK6); fish, Zebrafish, Danio rerio (Q6PH26); roundworm, Caenorhabditis elegans (Q9N2N3);
mosquito, Culex quinquefasciatus (B0W537); fungus, Aspergillus fumigatus (Q4WUC5); and slime mold, Dictyostelium discoideum
(Q8T6H3).þ, mutant position; fs, frameshift mutation; SM, splicemutation; E, exon; *, chain termination; del, deleted residue(s); under-
lined, ATP-binding motif.with respect to dystrophic calcifications than do ABCC6
mutations (Figure 6).29 Although calcifications of the
skin and peau d’orange changes of the retina have
been reported in patients carrying GGCX mutations,
retinal changes were relatively mild, and arterial calcifica-
tions have not been demonstrated in these patients so
far.29 It has been proposed that GGCX mutations lead
to decreased activation of the Gla proteins MGP and os-
teocalcin,29 which are known inhibitors of calcification.
With respect to the severe phenotype associated with
ABCC6 mutations in the present study, it is possible
that the decrease that GGCX mutations cause in g-glu-
tamyl carboxylation of calcification inhibitors might
not be sufficient to trigger artery calcification in vivo
and that additional factors apart from decreased activa-
tion of MGP are principal mediators in ABCC6-related
dystrophic calcification.
Early studies by Ilias et al. have proven a role of ABCC6
in the transport of glutathione-conjugated substratesThe Amin vitro,48 but the physiological substrate of this ABC trans-
porter is still elusive. Most recently, mutations in NT5E,
encoding CD73, a nucleotidase that generates adenosine
from extracellular adenosine monophosphate, were
shown to lead to a phenotype consisting of arterial calcifi-
cations of the lower extremities and distal joint calcifica-
tions (ACDC).13 In their study, the authors identified aden-
osine as a potent inhibitor of tissue-nonspecific alkaline
phosphatase (TNAP), whereas adenosine supplementation
reversed the increase in TNAP activity and mineralization
in CD73-deficient cells. On the basis of the clinical and
histological similarities of the ACDC phenotype with
that of PXE, Markello et al. postulated that ABCC6 might
be a transporter for adenosine.63 However, in our view,
the clinical overlap of the ACDC and PXE phenotypes is
less evident, and this view is in line with that of other
authors.64 Here, we establish that mutations in ENPP1
and ABCC6 can cause overlapping phenotypes (Figure 6),
suggesting that NPP1 and ABCC6 might share commonerican Journal of Human Genetics 90, 25–39, January 13, 2012 35
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Figure 6. Spectrum of Clinical Manifestations and Affected Tissues Associated with Mutations in ABCC6, ENPP1, and GGCX
Mutations of either ABCC6 or ENPP1 can cause the severe phenotype of generalized arterial calcification of infancy, which frequently
leads to death within the first year of life. Although mutations in ENPP1 can also cause PXE-like skin lesions and angioid streaks of
the retina in children who have GACI and survive the critical period of infancy, mutations in ABCC6 can also manifest later in life
with the ‘‘classic PXE‘‘ phenotype. Mutations in GGCX are associated with a PXE-like phenotype associated with mild retinopathy,
skin calcifications, severe cutis laxa, and deficiency of vitamin-K-dependent clotting factors. Hypophosphatemic rickets has been
observed frequently in patients with ENPP1 mutations but here was observed only in one proband carrying a mutation in ABCC6 on
one allele.downstream physiological pathways. ABCC6 mRNA
expression is abundant in the liver and kidneys, but it
has also been observed in PXE-affected tissues, including
the vessel wall.33 Accordingly, we have detected ABCC6
in the aorta from C57BL/6 mice (Supplemental Data),
and it is possible that local ABCC6 defects at multiple sites
in the body result in the PXE phenotype. However, our
findings cannot fully exclude the possibility that defi-
ciency of a circulating factor generated by the liver is the
driving force of dystrophic calcification in ABCC6 defi-
ciency.
More study, including functional genomics, and identifi-
cation of the elusive physiologic substrate(s) of the ABCC6
transporter are warranted in future studies if we are to
ascertain the factor(s) causing GACI in patients with
ABCC6 mutations. On the basis of the observed pheno-
typic overlap with GACI caused by ENPP1 mutations, it
is likely that this factor is a member of the same functional36 The American Journal of Human Genetics 90, 25–39, January 13, 2network in which NPP1 suppresses artery calcification. In
this network, PPi and Pi metabolism and adenosine
signaling are intimately linked, and degradation of the
artery calcification inhibitor PPi and generation of the crit-
ical artery calcification promoter Pi at sites of fibrillar type I
collagen expression plays a substantial role in driving
artery calcification.52,54
Summary
Studying a unique and relatively large cohort of subjects
and kindreds selected for severe, early-onset arterial calcifi-
cation, we have discovered pathogenic monoallelic and
biallelic mutations in ABCC6, previously associated with
PXE, in a subset of patients with GACI. Conversely, we
show that ENPP1-mutation-carrying patients, who pre-
sented with generalized arterial calcification of infancy,
can develop typical signs of PXE, including pseudoxan-
thomatous skin lesions and angioid streaks of the retina.012
The fact that even monoallelic mutations in ABCC6 were
associated with the severe phenotype of generalized arte-
rial calcification cannot fully be explained on the basis of
autosomal-recessive inheritance of PXE disease and may
suggest an unexpectedly wide phenotypic heterogeneity
ranging from mere skin calcifications and ocular findings
to severe artery calcification in early childhood. However,
mutations of other disease-modifying genes cannot yet
be ruled out. The fact that mutations in both ABCC6 and
ENPP1 can be associated with overlapping phenotypic
features furthermore provides evidence that deficiency of
either one of these molecules leads to alterations in the
same functional network. Determining the substrate(s) of
the ABCC6 transporter that promotes development of
GACI and better understanding how NPP1 and its enzy-
matic products modulate skin and eye tissue homeostasis
will require further study.Supplemental Data
Supplemental Data include three case reports and five figures.Acknowledgments
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Note Added in Proof
After this manuscript had gone into final preparation for
print, collaborators including Gary S. Gottesman, Center
for Metabolic Bone Disease and Molecular Research,
Shriners Hospital for Children, St. Louis, USA, detected
the bi-allelic mutation c.653A>T (p.Asp218Val) in ENPP1
in patient 13 of our cohort. We then confirmed the pres-
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